Preoperative Intravenous Iron Therapy in Patients With Gastric Cancer

Conditions:   Gastric Cancer;   Anemia;   Surgery;   Iron Deficiency Anemia;   Surgery--Complications Interventions:   Drug: Ferric carboxymaltose;   Drug: Placebos Sponsor:   Helsinki University Central Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

ConclusionsFOLFIRI  + S has signs of clinical activity in patients with advanced gastric and GEJ adenocarcinoma, and the side-effect profile was similar to previously reported studies. Current treatment paradigms in gastric cancer probably negate further study of this regimen.ClinicalTrials.gov identifier: NCT00524186.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
Conclusion Dyspepsia as a parameter to investigate gastric or oesophageal cancer contributes significantly to the growth in number of 2-week-wait referrals at a time when endoscopy units battle to meet demand. Our data show patients with uncomplicated dyspepsia rarely have gastric or oesophageal cancer and should not undergo endoscopies under the urgent 2-week-wait pathway.
Source: European Journal of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Original Articles: Gastroenterology Source Type: research
Conditions:   Gastric Cancer;   Anemia;   Surgery;   Iron Deficiency Anemia;   Surgery--Complications Interventions:   Drug: Ferric carboxymaltose;   Drug: Placebos Sponsor:   Helsinki University Central Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ConclusionsPatients with a low PMI experienced an increased incidence of hematological and non-hematological toxicities during preoperative chemotherapy for gastric cancer. Clinicians should be aware of these risks in this population.
Source: Surgery Today - Category: Surgery Source Type: research
The retrospective study was conducted to evaluate the efficacy and safety of careful dose modification of apatinib as third or further-line treatment in advanced gastric cancer (aGC) patients with poor performance status (PS = 2 or 3). Patients with aGC of poor PS who had received at least 2 lines of chemotherapy were treated with apatinib at a dose of 250 mg initially and best supportive care (BSC). During the whole treatment, the dose of apatinib was adjusted according to the status of PS (group treatment). Meanwhile, patients of poor PS (PS = 2 or 3) with aGC who received BSC alone after second or further-lin...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
ConclusionsPamiparib continues to be generally well tolerated and demonstrates antitumor activity in this update of an ongoing, phase 1 dose-escalation/expansion study in pts with advanced solid tumors.Clinical trial identificationNCT02361723.Editorial acknowledgementEditorial/writing support was provided by Ira Mills, PhD, and Shannon Davis at Ashfield Healthcare Communications, Middletown, CT.Legal entity responsible for the studyBeiGene.FundingBeiGene.DisclosureM. Voskoboynik: Honoraria (self): AstraZeneca; Honoraria (self): MSD Oncology; Travel / Accommodation / Expenses: Bristol-Myers Squibb. L. Mileshkin: Travel / Ac...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsPamiparib combined with ld TMZ continues to demonstrate promising antitumor activity and remains generally well tolerated in pts with advanced solid tumors.Clinical trial identificationNCT03150810.Editorial acknowledgementIra Mills, PhD, and Shannon Davis at Ashfield Healthcare Communications, Middletown, CT.Legal entity responsible for the studyBeiGene USA, Inc.FundingBeiGene USA, Inc.DisclosureA. Stradella: Honoraria (self): Roche; Honoraria (self): Celgene; Honoraria (self): Pfizer. M.L. Johnson: Research grant / Funding (institution): BerGenBio; Research grant / Funding (institution): Lilly; Research grant /...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsHM are the most frequent non BC SPM in p treated from BC; frequently they are therapy related neoplasms. Deescalating chemotherapy and radiotherapy in BC and finding genetic markers of early malignancy detection are mandatory.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsBased on confirmed PR (n  = 16/33, 48.5%), DHP107 demonstrated adequate efficacy with manageable toxicity in the first line HER2 negative recurrent/metastatic breast cancer patients. Phase III trial in breast cancer is ongoing in Korea and China.Legal entity responsible for the studyDaehwa Pharmaceuticals. Co. Ltd.FundingDaehwa Pharmaceuticals. Co. Ltd.DisclosureK.S. Lee: Advisory / Consultancy: Roche; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Norvatis; Advisory / Consultancy: Lilly; Research grant / Funding (institution): Dong-A pharm. K. Lee: Advisory / Consultancy, Speaker Bureau /...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Gastric cancer (GC) begins development in the mucus-producing cells which line the stomach [1]. Approximately 90 to 95% of all GCs are adenocarcinoma [6]. Since the middle of the 20th century, the incidence and mortality rates of GC in high-income countries of Europe and North America have been declining [13]. While there are many risk factors for the development of gastric cancer, such as Helicobacter pylori infection, chronic gastritis, pernicious anemia, intestinal metaplasia, gastric polyps, smoking, or having a family history of GC [11], obesity has not been named a risk.
Source: Surgery for Obesity and Related Diseases - Category: Surgery Authors: Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | Gastric (Stomach) Cancer | Gastroenterology | Hospitals | Iron | Research